• Crystal Violet Staining Solution: Mechanistic Insight & Tran

  2026-05-16

  This thought-leadership article provides a nuanced look at the mechanistic rationale, validated applications, and strategic integration of Crystal Violet Staining Solution in translational research. It contextualizes the dye’s role not only in established cell-based assays but also in the broader competitive and regulatory landscape, drawing on recent literature and practical workflow guidance. The discussion bridges mechanistic understanding with pragmatic recommendations, linking APExBIO’s product to reproducibility, workflow adaptability, and evolving research needs.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-05-15

  Schwartz (2022) introduces a methodological advance for distinguishing proliferation arrest from cell death in cancer drug studies, improving the interpretability of in vitro PARP inhibitor responses. This nuanced approach enables more robust mechanistic and translational research, particularly for therapies targeting DNA repair and drug-resistant tumor models.

• Inhibition of Renal OCT2/MATE1 by 5-HT3 Antagonists: Palonos

  2026-05-15

  This article reviews recent evidence on the in vitro inhibition of renal OCT2 and MATE1 transporters by 5-HT3 receptor antagonists, focusing on palonosetron hydrochloride. The findings have important implications for drug-drug interactions in cancer therapy and inform optimal antiemetic selection in research and clinical settings.

• EZ Cap™ Firefly Luciferase mRNA: Advances in Reporter Assays

  2026-05-14

  Explore how EZ Cap™ Firefly Luciferase mRNA revolutionizes bioluminescent reporter assays through enhanced translation and delivery. This article uniquely integrates recent LNP innovations, giving researchers a practical guide to maximizing assay sensitivity and reproducibility.

• Gamma-Linolenic Acid: Bridging Inflammation and Immunity

  2026-05-14

  This thought-leadership article explores the strategic integration of gamma-linolenic acid (GLA) in translational research. It synthesizes mechanistic, preclinical, and clinical insights, contextualizes GLA’s value versus other omega-6 fatty acids, and outlines actionable protocols. The piece distinguishes itself by bridging anti-inflammatory mechanisms to emerging immunomodulatory paradigms, referencing new evidence on humoral immunity. Protocol guidance, workflow challenges, and a forward-looking translational perspective are provided for researchers aiming to push the boundaries of anti-inflammatory and immunological innovation.

• (S)-(+)-Ibuprofen: A Stereoselective COX Inhibitor for Preci

  2026-05-13

  (S)-(+)-Ibuprofen is a selective COX inhibitor pivotal for inflammation pathway research. This article reveals new insights into its stereoselective synthesis, assay optimization, and translational impact—offering a perspective distinct from standard COX inhibitor reviews.

• Pioglitazone and PPARγ: Strategic Leverage in Translational

  2026-05-13

  This article dissects the mechanistic and translational value of Pioglitazone, a selective PPARγ agonist, in metabolic and inflammatory disease research. Integrating recent evidence on macrophage polarization, strategic protocol guidance, and competitive analysis, it offers actionable perspectives for translational researchers leveraging APExBIO’s Pioglitazone.

• High-Throughput BBB Permeability Prediction Using LLC-PK1-MD

  2026-05-12

  This study presents a robust in vitro blood-brain barrier (BBB) model integrating LLC-PK1-MOCK/MDR1 cells with lysosomal trapping correction, improving the predictive accuracy of drug permeability into the CNS. The model enables high-throughput screening, distinguishing passive diffusion, transporter-mediated efflux, and lysosomal sequestration, thereby streamlining early-stage CNS drug development.

• Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea): Applied To

  2026-05-12

  Harness the precision of Diuron in both plant biology and environmental toxicology research with evidence-backed protocols. Learn how recent mechanistic discoveries and workflow refinements can elevate reproducibility and mechanistic insight in studies of herbicide action and nephrotoxicity.

• THZ1 as a Covalent CDK7 Inhibitor: Precision Tools for Cance

  2026-05-11

  Explore how THZ1, a potent covalent CDK7 inhibitor, advances transcription regulation inhibitor research and enables precise interrogation of cancer cell vulnerabilities. This article delivers fresh insight into mechanistic selectivity and resistance—distinct from standard guides.

• Surrogate BBB Model Enhances High-Throughput CNS Drug Screen

  2026-05-11

  This study introduces a robust in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells and a lysosomal trapping correction protocol, enabling accurate, high-throughput prediction of BBB permeability. The model's strong correlation with in vivo brain distribution offers significant advancements for early-stage CNS drug development and translational research.

• hiPSC-Derived Intestinal Organoids for Human Pharmacokinetic

  2026-05-10

  This study introduces a streamlined protocol to generate human pluripotent stem cell-derived intestinal organoids with sustained self-renewal, enabling robust in vitro pharmacokinetic modeling. The resulting organoids recapitulate key features of human intestinal epithelium, providing a more physiologically relevant system for drug absorption and metabolism studies than conventional models.

• ROS-Degradable Lipid Nanoparticles for Tumor-Selective mRNA

  2026-05-09

  This article reviews a recent study introducing a combinatorial library of ROS-degradable lipid nanoparticles that enable selective mRNA delivery and gene expression in tumor cells. The approach demonstrates potent suppression of mutant RAS signaling, offering a targeted and biodegradable solution for advancing mRNA cancer therapeutics.

• Phebestin: A Nanomolar Aminopeptidase Inhibitor for Malaria

  2026-05-08

  This study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a potent antiplasmodial agent with nanomolar activity against both chloroquine-sensitive and resistant Plasmodium falciparum strains. Its low cytotoxicity and unique mechanism targeting parasite-specific aminopeptidases present promising directions for malaria drug discovery.

• Applied Workflows with the HyperScribe T7 High Yield Cy5 RNA

  2026-05-08

  The HyperScribe T7 High Yield Cy5 RNA Labeling Kit offers unmatched flexibility for generating fluorescent RNA probes, enabling precise in situ hybridization and advanced gene expression studies. Discover optimized protocols, troubleshooting strategies, and practical insights that set this Cy5 RNA labeling kit apart for both routine and cutting-edge molecular applications.

401 records 8/27 page Previous Next First page 上5页 678910 下5页 Last page